RT Journal Article
SR Electronic
T1 Immune transcriptomes of highly exposed SARS-CoV-2 asymptomatic seropositive versus seronegative individuals from the Ischgl community
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.09.01.20185884
DO 10.1101/2020.09.01.20185884
A1 Lee, Hye Kyung
A1 Knabl, Ludwig
A1 Pipperger, Lisa
A1 Volland, Andre
A1 Furth, Priscilla A.
A1 Kang, Keunsoo
A1 Smith, Harold E.
A1 Ludwig, Knabl
A1 Bellmann, Romuald
A1 Bernhard, Christina
A1 Kaiser, Norbert
A1 Gänzer, Hannes
A1 Ströhle, Mathias
A1 Walser, Andreas
A1 Laer, Dorothee von
A1 Hennighausen, Lothar
YR 2020
UL http://medrxiv.org/content/early/2020/09/02/2020.09.01.20185884.abstract
AB To investigate prevalence of ongoing activation of inflammation following asymptomatic SARS-CoV-2 infection we characterized immune cell transcriptomes from 43 asymptomatic seropositive and 52 highly exposed seronegative individuals with few underlying health issues following a community superspreading event. Four mildly symptomatic seropositive individuals examined three weeks after infection as positive controls demonstrated immunological activation. Approximately four to six weeks following the event, the two asymptomatic groups showed no significant differences. Two seropositive patients with underlying genetic disease impacting immunological activation were included (Cystic Fibrosis (CF), Nuclear factor-kappa B Essential Modulator (NEMO) deficiency). CF, but not NEMO, associated with significant immune transcriptome differences including some associated with severe SARS-CoV-2 infection (IL1B, IL17A, respective receptors). All subjects remained in their usual state of health from event through five-month follow-up. Here, asymptomatic infection resolved without evidence of prolonged immunological activation. Inclusion of subjects with underlying genetic disease illustrated the pathophysiological importance of context on impact of immunological response.Competing Interest StatementThe authors have declared no competing interest.Clinical Trial1100/2020 and 1111/2020Funding StatementThis work was supported by the Intramural Research Program (IRP) of National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The ethical committee of the Medical University of Innsbruck approved the study (EC numbers: 1100/2020 and 1111/2020).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe RNA-seq data for patients will be uploaded in GEO.